Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 15, 2009. The report details GSK's strategic response to the emergence of the A (H1N1) influenza strain, focusing on the development, manufacturing, and supply of a candidate adjuvanted vaccine and the continued production of seasonal influenza vaccines.
Key Financial Metrics
The filing text does not provide specific financial values for revenue, profit, cash flow, margins, debt, or liquidity. The document is an operational update regarding public health preparedness rather than a financial earnings report.
Material Changes and Operational Updates
- Vaccine Orders: GSK has received orders from several governments to stockpile a new candidate A (H1N1) adjuvanted influenza vaccine.
- Production Timeline: Manufacturing is expected to commence once the virus seed is provided by the World Health Organization (WHO). The first doses are projected to be available four to six months post-seed availability, subject to regulatory approval.
- Seasonal Vaccine Status: Production of the seasonal influenza vaccine for the 2009/2010 Northern Hemisphere season continues as planned, with completion expected by the end of July 2009.
- Regulatory Pathway: GSK leverages a 2008 European licence for a pandemic vaccine based on a 'mock-up' dossier (H5N1 strain) to expedite the registration of the new A (H1N1) vaccine.
Government Supply Agreements
| Government | Agreement Details |
|---|---|
| United Kingdom | Supply of 60 million doses of the candidate A (H1N1) adjuvanted vaccine. |
| France | Intention to purchase 50 million doses of the candidate A (H1N1) vaccine. |
| Belgium | Intention to purchase 12.6 million doses for stockpiling and population protection. |
| Finland | Agreement to supply 5.3 million doses of H1N1 antigen to be used with existing adjuvant stockpiles. |
Guidance, Outlook, and Risks
- Donation Commitment: GSK will convert its intended donation of 50 million doses of H5N1 pre-pandemic vaccine to the WHO into the new candidate A (H1N1) adjuvanted vaccine once production begins.
- Developing Nations: Future supply to developing countries will follow a tiered-pricing policy based on World Bank classifications and GAVI eligibility.
- Antiviral Medication: Discussions are ongoing with governments to increase production and supply of Relenza, an antiviral effective against both influenza A and B.
- Risk Factors: The filing includes a cautionary statement that forward-looking statements are subject to risks and uncertainties. Actual results may differ materially from projections due to factors described in the 2008 Annual Report on Form 20-F.
Investor Verification Checklist
- Verify the timeline for WHO virus seed availability, as this is the critical path dependency for manufacturing start.
- Confirm the status of regulatory approvals in key markets (EU, US) for the A (H1N1) candidate vaccine.
- Monitor the conversion of the 50 million dose H5N1 donation to the A (H1N1) vaccine and the associated logistics.
- Assess the impact of the pandemic response on the capacity and revenue of the seasonal influenza vaccine business for the 2009/2010 season.
- Review the 2008 Form 20-F for detailed risk factors referenced in the forward-looking statement.